# Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability

> **NCT03962998** · EARLY_PHASE1 · COMPLETED · sponsor: **MediBeacon** · enrollment: 22 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Lactulose/Rhamnose solution
- **DRUG:** MB-102

## Key facts

- **NCT ID:** NCT03962998
- **Lead sponsor:** MediBeacon
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-27
- **Primary completion:** 2021-10-05
- **Final completion:** 2021-10-05
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03962998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03962998, "Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03962998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*